Navigation Links
Slone Partners Fills VP of Scientific Affairs Role for Cambridge Biomedical

National executive search firm, Slone Partners, announces the placement of Linda Robbie, PhD, a well-versed leader with extensive assay development and biomarker expertise, as VP of Scientific Affairs at Cambridge Biomedical.

Established in 1997, Cambridge Biomedical is a Boston CRO specializing in bio-analytical assay development and sample testing services. The organization acts as a leading provider of customized assays for small and large molecules, biomarkers, and diagnostics.

In her new role, Dr. Robbie will serve as the head of science and innovation and will lead and direct all initiatives related to science and technology, clinical operations, and project management.

“Linda is an exceptional addition to our leadership team. Leveraging her unique people management skills and years of successful technology implementation, she will act as our key scientific point person interfacing with both our clients and internal teams. We are pleased to have worked with Slone Partners on this important search. Linda is truly a remarkable scientist and a perfect cultural fit for our organization,” said Chairwoman and CEO of Cambridge Biomedical, Barbara Osband.

Prior to joining Cambridge Biomedical, Dr. Robbie served as the Global Senior Director of Biomarkers and Translational Science at Q² Solutions Laboratories, a Quintiles-Quest Joint Venture, where she led assay development teams in the U.S. and overseas.

Dr. Robbie earned a Bachelor of Science, with honors, in Biochemistry from Heriot-Watt University in Edinburgh, Scotland, and a PhD, in Immunohematology from the Institute of Medical Science, Aberdeen University, Scotland.

About Slone Partners

Founded in 2000, Slone Partners is a premier executive search firm that specializes in recruitment for the life sciences, diagnostics, clinical trials, contract research, therapeutics, healthcare information technology, and laboratory testing industries with offices in Boston, Washington, D.C. and San Francisco. Innovative, world-class organizations from across the nation have chosen Slone Partners to fill their key positions. To learn more about Slone Partners’ services, visit:

About Cambridge Biomedical

Cambridge Biomedical, based in Boston, MA, supports sponsors by developing customized assays for small and large molecules, biomarkers and other critical analytes, along with validation and sample testing in CLIA-certified and CAP-accredited, GLP/GCLP-compliant facilities. Cambridge Biomedical has extensive expertise in assay development, optimization and validation, and offers analytical support for PK/PD studies, biomarker development, clinical assay development, assay validation, specimen analysis and testing services. For more information, visit the website at, email info(at)cambridgebiomedical(dot)com or call 617.456.0700.

Read the full story at

Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved

Related biology technology :

1. Slone Partners Hosts Precision Medicine Event Led by Michael Pellini, MD with Panelists Troy Cox, Barbara Weber, MD and Roman Yelensky, PhD
2. Slone Partners Pledges its Support as Corporate Benefactor for the 2017 Executive War College
3. Slone Partners Places Chief Executive Officer at La Peer Health Systems
4. Slone Partners Places Chief Executive Officer at Avomeen Analytical Services
5. Slone Partners Designated by Hunt Scanlon Media as one of the “Top 50 Healthcare and Life Science Search Firms”
6. Slone Partners Places President & Chief Commercial Officer at GenePeeks
7. Slone Partners Sponsors the SCOPE Summit for Clinical Ops Executives 2017
8. Slone Partners Fills Head of Sales at Optimal Medicine
9. Executive Search Firm Slone Partners Expands With New San Francisco Office
10. Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation
11. Slone Partners CEO & President Speak about Hiring Challenges in Molecular Diagnostics at Executive War College 2013
Post Your Comments:
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
(Date:10/10/2017)... , Oct. 10, 2017 SomaGenics announced ... the NIH to develop RealSeq®-SC (Single Cell), expected to ... profiling small RNAs (including microRNAs) from single cells using ... highlights the need to accelerate development of approaches to ... "New techniques for measuring levels of ...
(Date:10/9/2017)... ... October 09, 2017 , ... The award-winning American Farmer television series will feature ... Farmer airs Tuesdays at 8:30aET on RFD-TV. , With global population estimates nearing ... how to continue to feed a growing nation. At the same time, many of ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... instruments and applications consulting for microscopy and surface analysis, Nanoscience Instruments is ... Nanoscience Analytical offers a broad range of contract analysis services for advanced ...
Breaking Biology Technology:
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
Breaking Biology News(10 mins):